Biopolymer implants enhance the efficacy of adoptive T-cell therapy

Nature Biotechnology

Volumn 33, Issue 1, 2015, Pages 97-101

  Stephan, Sirkka B ^a   Taber, Alexandria M ^a   Jileaeva, Ilona ^a   Pegues, Ericka P ^a   Sentman, Charles L ^b   Stephan, Matthias T ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CYTOLOGY; DISEASES; ENZYME INHIBITION; LYMPHOCYTES; SCAFFOLDS (BIOLOGY); TUMORS;

BIOACTIVE POLYMERS; BREAST CANCER; CLINICAL UTILITY; CURATIVE EFFECTS; OVARIAN CANCERS; T CELL DELIVERIES; TUMOR MICROENVIRONMENT; TUMOR TARGETING;

T-CELLS;

BIOPOLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER REGRESSION; CELL THERAPY; CLINICAL EFFECTIVENESS; FEMALE; IMPLANT; LYMPH NODE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR XENOGRAFT; ADOPTIVE TRANSFER; IMMUNOLOGY; PROSTHESES AND ORTHOSES;

ADOPTIVE TRANSFER; BIOPOLYMERS; PROSTHESES AND IMPLANTS; T-LYMPHOCYTES;

EID: 84922664081     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3104     Document Type: Article

References (30)

1. Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641-645 (2014).
2. Krebs, S., Rodriguez-Cruz, T.G., Derenzo, C., Gottschalk, S. Genetically modified T cells to target glioblastoma. Front. Oncol. 3, 322 (2013).
3. Kandalaft, L.E., Powell, D.J. Jr., Coukos, G. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J. Transl. Med. 10, 157 (2012).
4. Rosenberg, S.A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550-4557 (2011).
5. Robbins, P.F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917-924 (2011).
6. Hinrichs, C.S.a. HPV-targeted tumor-infiltrating lymphocytes for cervical cancer. J. Clin. Oncol. 32, 5s (suppl; abstr LBA3008) (2014).
7. Kershaw, M.H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106-6115 (2006).
8. Yaghoubi, S.S. et al. Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nat. Clin. Pract. Oncol. 6, 53-58 (2009).
9. Lamers, C.H. et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol. Ther. 21, 904-912 (2013).
10. Baldwin, A.D., Kiick, K.L. Polysaccharide-modified synthetic polymeric biomaterials. Biopolymers 94, 128-140 (2010).
11. Wojtowicz, A.M. et al. Coating of biomaterial scaffolds with the collagen-mimetic peptide GFOGER for bone defect repair. Biomaterials 31, 2574-2582 (2010).
12. Miller, M.J., Wei, S.H., Cahalan, M.D., Parker, I. Autonomous T cell trafficking examined in vivo with intravital two-photon microscopy. Proc. Natl. Acad. Sci. USA 100, 2604-2609 (2003).
13. Mamaeva, V., Sahlgren, C., Linden, M. Mesoporous silica nanoparticles in medicine-recent advances. Adv. Drug Deliv. Rev. 65, 689-702 (2013).
14. Rubinstein, M.P. et al. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc. Natl. Acad. Sci. USA 103, 9166-9171 (2006).
15. Maus, M.V. et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat. Biotechnol. 20, 143-148 (2002).
16. Janát-Amsbury, M.M., Yockman, J.W., Anderson, M.L., Kieback, D.G., Kim, S.W. Comparison of ID8 MOSE and VEGF-modified ID8 cell lines in an immunocompetent animal model for human ovarian cancer. Anticancer Res. 26, 2785-2789 (2006).
17. Conejo-Garcia, J.R. et al. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat. Med. 10, 950-958 (2004).
18. Charles, K.A. et al. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J. Clin. Invest. 119, 3011-3023 (2009).
19. Scarlett, U.K. et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J. Exp. Med. 209, 495-506 (2012).
20. Sentman, C.L., Meehan, K.R. NKG2D CARs as cell therapy for cancer. Cancer J. 20, 156-159 (2014).
21. Ali, O.A., Emerich, D., Dranoff, G., Mooney, D.J. In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci. Transl. Med. 1, 8ra19 (2009).
22. Kauer, T.M., Figueiredo, J.L., Hingtgen, S., Shah, K. Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat. Neurosci. 15, 197-204 (2012).
23. Hori, Y., Winans, A.M., Huang, C.C., Horrigan, E.M., Irvine, D.J. Injectable dendritic cell-carrying alginate gels for immunization and immunotherapy. Biomaterials 29, 3671-3682 (2008).
24. Pule, M.A. et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14, 1264-1270 (2008).
25. Peres, E. et al. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors. Neuropediatrics 39, 151-156 (2008).
26. Tumeh, P.C. et al. The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy. J. Immunother. 33, 759-768 (2010).
27. Rosenberg, S.A. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat. Rev. Clin. Oncol. 8, 577-585 (2011).
28. Stone, J.D., Chervin, A.S., Schreiber, H., Kranz, D.M. Design and characterization of a protein superagonist of IL-15 fused with IL-15Ralpha and a high-affinity T cell receptor. Biotechnol. Prog. 28, 1588-1597 (2012).
29. Boontheekul, T., Kong, H.J., Mooney, D.J. Controlling alginate gel degradation utilizing partial oxidation and bimodal molecular weight distribution. Biomaterials 26, 2455-2465 (2005).
30. Erskine, C.L., Henle, A.M., Knutson, K.L. Determining optimal cytotoxic activity of human Her2neu specific CD8 T cells by comparing the Cr51 release assay to the xCELLigence system. J. Vis. Exp. 2012, e3683 (2012).